The major objective of this course is to provide a detailed insight into the practical aspects and approaches of process scale-up for different unit operations and technologies.
January 2016 to start new era for pharma companies in Europe
The past decade has witnessed a wave of global transparency in the pharmaceutical industry, and 2015 has marked the start of a new era in Europe. From January 2016, pharma companies will make their transfers of value public to healthcare professionals and healthcare organisations in Europe.
Therefore, Fleming Europe has decided to gather the experts at its 4th edition of Corporate Compliance and Transparency in the Pharmaceutical Industry and make sure that these companies have entered the new year prepared.
On the 24th of February 2016, legal and compliance professionals from Johnson & Johnson, Novo Nordisk, Sandoz, Mylan, Actavis, Boehringer-Ingelheim, GlaxoSmithKline and many more will meet in Zurich to prepare for not only a huge technical challenge but also a major cultural shift.
During the two focused days, attendees will get an update on the Disclosure Code implementation and its first outcomes and learn how to optimise interactions with HCPs and HCOs through a fully compliant and transparent strategy.
Richard Bergstrom, Director General at EFPIA, will open the first conference day with an on-stage interview. Representatives from Novo Nordisk will present their local perspective and lessons learned. The Director General of the European Generic and Biosimilar Medicines Association will outline the Code of Conduct for the European Generic and Biosimilar Medicines Industry.
The second conference day will focus on risk assessment, communication with third parties along with their training and monitoring, internal investigations and the best practices in compliance programme structure and their effectiveness.
If you don't want your ideas to sit and gather dust, join Fleming Europe's 4th edition of Corporate Compliance and Transparency in the Pharmaceutical Industry. You are also welcome to join the discussions in the Pharma SFE & Marketing Forum
Interested in this topic?
Targeted Drug Delivery
Gain detailed overview of the newest strategies in drug delivery and targeting.
Next Generation Antibody Therapeutics
This focused 2-day training will cover the discovery, engineering and production of next-generation antibodies, antibody fragments, bispecific Abs, innovative ADCs and more. Follow the path from their discovery and selection through engineering and expression to production and regulatory issues.
White Paper: Beyond the Cold Chain
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?